These randomized controlled trials strongly support the use of SGLT2 inhibitors to reduce ALT and AST levels and improve liver fibrosis in patients with T2DM and NAFLD. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.